Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials

Liknande verk

• Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
  av: Coates, LC, et al.
  Publicerad: (2022)
• Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
  av: Coates, L, et al.
  Publicerad: (2022)
• Sustained very low disease activity and remission in psoriatic arthritis patients
  av: Lubrano, E, et al.
  Publicerad: (2019)
• Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
  av: Coates, L, et al.
  Publicerad: (2017)
• Considerations for the definition of remission criteria in psoriatic arthritis
  av: Mease, P, et al.
  Publicerad: (2017)